R 763

Drug Profile

R 763

Alternative Names: AS703569; R763

Latest Information Update: 01 Apr 2011

Price : $50

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer Merck Serono
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Aurora kinase A inhibitors; Aurora kinase B inhibitors; Aurora kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Haematological malignancies; Solid tumours

Most Recent Events

  • 28 Feb 2010 Merck Serono expects to wind down the various clinical trials for R 763 and plans to return the drug back to Rigel
  • 19 Nov 2009 Efficacy, adverse events & pharmacokinetic data from a phase I trial in Solid tumours presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
  • 19 Nov 2009 Preclinical pharmacodynamics data in Haematological malignancies presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top